The average age at first injection was 51.4 years old with standard deviation of 12.2 years. Seven-hundred and six patients were female and 73 were male. Patients' race and skin type were diverse: Caucasian (557), Hispanic or South/Central American (82), and Middle Eastern (59), Asian (36), African American (5) , Other (20) . Fitzpatrick skin type of patients varied from type 2(9) type 3 (447), type 4 (317), type 5 (4) and type 6 (1).
Other facial cosmetic surgical procedures reported in the affirmative on chart review were: rhytidoplasty (123), blepharoplasty (77), and rhinoplasty (40). Other cosmetic procedures reported in the affirmative by chart review were: Neuromodulator (Botox, Allergan and Dysport, Galderma Laboratories) (634), Laser, NOS (197), Photorejuvenation or IPL (114), Thermage  , Valeant Pharmaceutical North America, LLC (196), and Ultherapy  , Merz Pharma (205). Other HA (hyaluronic acid type fillers reported in the affirmative by these patients included: Restylane  , Galderma Laboratories (222) and Juvederm  , Allergan (278). Other fillers reported: Radiesse  (Calcium hydroxylapatatite), Merz Pharma and Sculptra  (Poly-L-Lactic acid), Galderma Laboratories (355).
As of May, 2016, 43 patients with nodular complications were reported in clinic notes of the 779 patients. However, 10 patients had complications in multiple facial areas ( Table 1 ).
The average time to first sign of complication for all complications was 1.2 years. Data was grouped based on infra-orbital and "other areas of face" based on prior data collection. The other "areas of face regions" time to complication was 1.45 years with a range of 0.02 to 4.61 years. The average time to first sign of complication in the infraorbital region was slightly less at 1.1 year with a range of 0.03 to 3.8 years.
Prior facelift, blepharoplasty, Fitzpatrick skin classification was not associated with increased risk of nodular complication of the infra-orbit area or other areas of the face. Autoimmunity was approaching significance in the complication of the other areas of the face at p = 0.07 but not with the infra-orbital group.
Of the forty-three patients, 34 resolved with multiple steroid injections averaging 3.7 injections to resolution. Five were lost to follow up. Four have had ongoing injections with one of these patients undergoing surgical resection of multiple eye and peri-oral biopsy confirmed granulomas.
General treatment consisted of intra-lesional Triamcinolone 40mg/ml of the nodule at injection site. If no improvement was noted at 6 weeks, a 50:50 mixture of Triamcinolone and Fluorouracil (5-FU) was utilized as per Vent and Lemperle in 2014 [5] . Fluorouracil in combination with intra-lesional triamcinolone was also utilized as per Lemperle et al in 2006 [6] .
Discussion
Bellafill (Suneva Medical, San Diego, CA) is the only FDAapproved PMMA injectable filler available in the United States. First approved as Artefill in 2007 as dermal filler for NL folds, it recently became approved for acne scarring in 2014 for the treatment of moderate to severe, facial acne scars. PMMA is recommended to be injected either subdermal or epi-periosteum only. In this large retrospective study, the complication rate for NL fold injection is 1.6 % which is slightly lower than Cohen et al who reported in 2015 a rate of 1.7% [7] . Both of which are higher than the previously reported 0.1% [8] . Karnik et al showed substantial effectiveness in the treatment of atrophic acne scars in the face with only mild, reversible adverse events [9] . Lee and Lorenc report, patients best treated by PMMA are those with atrophic distensible acne scarring and injecting into the deep dermis [10] . In this study, complication of injection of PMMA into scar was 0% but with a limited sample size of 8 patients.
PMMA has been reported as a semi-permanent filler used in other areas of the face by respected practitioners. Thomas in 2016 discussed that there are multiple other injectable fillers that can be used in nasal reconstruction. Examples include silicone, both liquid and solid/sheet form; Artecoll, which is bovine collagen; and PMMA [11] . Mills reported successful use in malar atrophy with an 87.5% success rate and no adverse reactions in 24 patients [12] .
PMMA's use has been expanded in cosmetic facial rejuvenation to other areas of the face or hands. In the Author's clinic, patients seeking a more long-lasting response to filler injection were informed of the "off-label" use of the semi-permanent PMMA filler. Patients who wished to proceed received 1-7 injections of PMMA to regions of the face including: Peri-oral (589), Infra-orbital (395), Nasolabial folds (379), Temporal (212), Cheek (161), Glabella (99), and Scar area (8) . Given the potential for nodular and granuloma complications, these patient's charts were reviewed for these complications. In this retrospective study, we present the largest patient review of PMMA filler used for multiple facial rejuvenation sites to date.
The infra-orbital area was the most common place to have the nodular complication reported. It is possible that the rate of nodular reactions might be the same as for other areas but the detection of the nodules may be more obvious. The infra-orbital thin skin being less forgiving to practitioner and patient than the thicker skin in other areas of the face. For example, in the peri-oral area, nodular complications were less obvious and mostly palpable. Lemperle et al recommended a strictly epi-periosteal injection beneath the orbicularis oculi muscle and just superficial to the insertion of the orbital septum [5, 13] .
While the overall nodularity complication rate was 5.4%, the infra-orbital (6.1%) and peri-oral (3.1%) areas which had higher complications may have some common issues as well. The infraorbital and peri-oral sphincters have similarities regarding the circumferential muscular motion. Jordan and Stoica reported 3 patients with filler migration and made an excellent review on possible mechanisms for this migration. Motion of the orbicularis muscle or muscles of facial expression could promote dislocated granulomas from filler [1] .
Ten patients had nodularity in multiple facial areas injected with PMMA. Looking specifically at these patients, we could find no statistical test to infer causation or correlation including number of injections which varied widely. One of these patients, after resolution of small granuloma wished to proceed again with PMMA filler later which was discouraged.
Limitations to the study include lack of excisional or incisional biopsy in most patients. Nodular complication was defined as any lumpiness that required treatment with injection regardless of before or after 90 days. While Cohen separated "early" (<90 days) associated with implant procedure and "late" potentially a granulomatous process, we elected to treat any unwanted nodule needing steroid treatment as a complication [7] .
Other limitations include the retrospective chart review and patients lost to follow up. Significant complications, however, are unlikely to be missed or lost to follow up in the population of cosmetic patients. Concerning medical issues while noted on intake exam, autoimmunity takes many years to diagnose and is sometimes not considered relevant in the patient's mind when entering a cosmetic facility. The authors noted it was approaching statistical significance at p= 0.07 in the complication "other areas of face" stratified group. It may be wise to specifically question patients about this history.
In conclusion, this study has shown that injection of a permanent PMMA filler in the context of facial rejuvenation while possible to create clinically relevant results, may produce the possibility of nodular complication in a significant number of patients. The incidence of granuloma complication is reported in the nasolabial fold is 1.7% [7] . While not biopsy confirmed, comparable rates of nodularity were noted in the nasolabial fold area but were much higher in the infra-orbital and peri-oral areas. Also, adverse reactions may occur as late as 4.6 years. The 'Holy Grail' of cosmetic filler for patients is to not have to re-inject the fillers at intervals. At present, the tenacity of the PMMA filler with incomplete dissolution may be ill suited to some patients and some regions of the face. Even where PMMA filler is FDA approved in the face, significant caution must be taken with full disclosure to the patient leading to informed consent. Longer term follow-up seems to be necessary and beneficial to a cosmetic practice.
